Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

Abstract

Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

• Authors: Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Mahmoud Hashim, Yannan Hu, Denis Caillot, Lofti Benboubker, Sonja Zweegman, Maximilian Merz, Katja Weisel, Hans Salwender, Elias K Mai, Hartmut Goldschmidt, Uta Bertsch, Véronique Vanquickelberghe, Tobias Kampfenkel, Carla de Boer, Stanimira Krotneva, Irina Proskorovsky, Jianming He, Annette Lam, Charlene Lee, Sarah Cote, Pieter Sonneveld
• Journal: Immunotherapy (Immunotherapy) Vol. 13 Issue 2 Pg. 143-154 (02 2021) ISSN: 1750-7448 [Electronic] England
• PMID: 33228440 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• daratumumab
• Thalidomide
• Bortezomib
• Dexamethasone
• Cyclophosphamide

Topics

• Adult
• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bortezomib (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Dexamethasone (therapeutic use)
• Female
• Humans
• Induction Chemotherapy
• Male
• Middle Aged
• Multiple Myeloma (drug therapy, mortality, pathology, surgery)
• Progression-Free Survival
• Randomized Controlled Trials as Topic
• Stem Cell Transplantation
• Survival Rate
• Thalidomide (therapeutic use)
• Transplantation, Autologous